TY - JOUR
T1 - Treat to target in Behcet's disease
T2 - Should we follow the paradigm of other systemic rheumatic diseases?
AU - Fragoulis, George E.
AU - Bertsias, George
AU - Bodaghi, Bahram
AU - Gul, Ahmet
AU - van Laar, Jan
AU - Mumcu, Gonca
AU - Saadoun, David
AU - Tugal-Tutkun, Ilknur
AU - Hatemi, Gulen
AU - Sfikakis, Petros P.
N1 - Publisher Copyright:
© 2022
PY - 2023/1
Y1 - 2023/1
N2 - During the last decades the efficacy of biologic agents, mainly of anti-TNFs, in controlling the activity of serious manifestations of Behcet's Disease (BD) has been established. On the other hand, the clinical heterogeneity of BD has precluded the validation of a widely-accepted composite index for disease assessment and for target disease-state definitions, such as low disease activity and remission, and the testing of their implementation in clinical practice. Therefore, in contrast to other systemic rheumatic diseases, a treat-to-target strategy has not yet been developed in BD. There are several challenges towards this approach, including standardization of outcome measures for assessing the disease activity in each-affected organ and construction of a composite disease activity index. The challenges for the development of a treat-to-target strategy and possible solutions are discussed in this position paper, which stemmed from a round table discussion that took place in the 19th International Conference on BD.
AB - During the last decades the efficacy of biologic agents, mainly of anti-TNFs, in controlling the activity of serious manifestations of Behcet's Disease (BD) has been established. On the other hand, the clinical heterogeneity of BD has precluded the validation of a widely-accepted composite index for disease assessment and for target disease-state definitions, such as low disease activity and remission, and the testing of their implementation in clinical practice. Therefore, in contrast to other systemic rheumatic diseases, a treat-to-target strategy has not yet been developed in BD. There are several challenges towards this approach, including standardization of outcome measures for assessing the disease activity in each-affected organ and construction of a composite disease activity index. The challenges for the development of a treat-to-target strategy and possible solutions are discussed in this position paper, which stemmed from a round table discussion that took place in the 19th International Conference on BD.
UR - http://www.scopus.com/inward/record.url?scp=85142719362&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2022.109186
DO - 10.1016/j.clim.2022.109186
M3 - Article
C2 - 36410686
AN - SCOPUS:85142719362
SN - 1521-6616
VL - 246
JO - Clinical Immunology
JF - Clinical Immunology
M1 - 109186
ER -